Clinical Trial Update: A Comparison of Symbicort® Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma [Phase 3]

View source ↗

Summary

Phase 3 trial comparing Symbicort single inhaler therapy with conventional best practice for persistent asthma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Symbicort (budesonide/formoterol)

Snippet

Sponsor: AstraZeneca | Conditions: Asthma | Phase 3 | Status: COMPLETED | Results posted: 2012-08-14